ABSTRACT Camptothecin (CPT), a plant alkaloid with antitumor activity, is a specific inhibitor of eukaryotic DNA topoisomerase 1. We have previously isolated and characterized a CPT-resistant topoisomerase I isolated from a CPT-resistant human leukemia cell line, CPT-K5. cDNA clones of topoisomerase I were isolated from the CPT-resistant and the parental CPT-sensitive cell lines, respectively. Sequencing of the clones identified two mutations in the cDNA isolated from the resistant cells, which cause amino acid changes from aspartic acid to glycine at residues 533 and 583 of the parental topoisomerase 1. When the CPT-K5 topoisomerase I was expressed in E. coil as a fusion protein with Staphylococcal Protein A fragment, the activity was resistant to CPT at a dose level up to 125 1M, whereas the parental fusion protein was sensitive to CPT as low as 1 ,aM. The resistance index (>125) of the CPT-K5 fusion topoisomerase I is similar to that of the native CPT-K5 topoisomerase 1. These results indicate that either or both of the two amino acid changes identified in the mutant enzyme is responsible for the resistance to CPT.
INTRODUCTION
. In eukaryotes, these enzymes are implicated to be involved in the replication of DNA and chromosomal segregation, as well as in the transcription of specific genes (2) .
Recent studies have identified the DNA topoisomerases as targets of a number of anticancer drugs (3) . The majority of these therapeutics acts on DNA topoisomerase II; however, a plant alkaloid camptothecin (CPT) acts specifically on eukaryotic DNA topoisomerase I (4). CPT, an alkaloid isolated from Camptotheca acuminata, has a strong antitumor activity against a wide range of experimental tumors (5) . CPT inhibits RNA and DNA synthesis and causes rapid and reversible fragmentation of DNA in mammalian cells (6) (7) (8) . The inhibitory effect of CPT on topoisomerase I catalysis was shown to be related to the drugmediated stabilization of a cleavable complex (3, 9) .
Previously, we reported the isolation and characterization of a CPT-resistant cell line (CPT-K5) from a human acute lymphoblastic leukemia cell line (RPMI8402) (10) . It was shown that CPT-K5 cells possess a CPT-resistant DNA topoisomerase I with the same molecular weight and proteolytic map as the wildtype enzyme. The CPT-K5 enzyme had other altered enzymatic properties such as its higher efficiency of recognition of specific sequences and higher stability of cleavable complexes (11) . Thus, the enzyme site(s) or domain(s) affected by CPT and the mutation conferring resistance to the drug are determinants responsible for strand passage and/or religation steps. The relationship between the mutation site(s) and the active site of the enzyme is to be clarified. Several alternative mechanisms might be possible for the acquisition of the resistance: such as mutation of the structural gene, post-translational modification or expression of a 'pseudo'-gene whose product is resistant to CPT (12) . As a first attempt to address this problem, we have attempted cloning and sequencing of the cDNAs of the wild-type and CPT- K5 topoisomerase I. Here we report the molecular cloning of cDNAs; of topoisomerase I from the mutant and the wild-ty cells.
Comparison of the deduced amino acid sequences revealed amino acid changes at two positions at about one-third from the carboxyl terminus of the enzyme. Expression of the mutant enzyme in E. coli revealed that the two amino acid changes found in the mutant enzyme are responsible for the resistance to CPT. Comparison of the amino acid sequence with those of other eukaryotic topoisomerase I, i.e. those of Saccharomyces cerevisiae and Schizosaccharomyces pombe, showed that the region in which the mutations occurred is highly conserved (13 (20) .
Other procedures Blot hybridization was performed according to standard procedures (21) . cDNA sequences were determined by the dideoxynucleotide chain-termination method (22) following subcloning cDNA inserts into M13 or pUC19. Immunoblot analysis was carried out as described (10, 23) .
RESULTS
Genomic ogizations and transcripts of DNA topoisomerase I genes in the wild-type and the CPT-K5 ceils A Southern blot of the wild-type and the CPT-K5 cellular DNA digested with several restriction enzymes was probed with a 0.42 kb HindM-TaqI fragment (from nucleotide 1661 to 2081; numbered according to Ref. 24) of phtopl ( Fig. 2 ). As shown in Fig. 1 (a) , the genomic organization of topoisomerase I in the mutant cells seems to be similar to that of the wild-type cells suggesting that there is no detectable genomic disorders such as gene amplification or chromosomal rearrangement around topoisomease I gene of the mutant cell. A Northem blot analysis showed that the expression level of topoisomerase I in fthe mutant cells is similar to that in the wild-type cells withi the size of 4.2 kb ( Fig. 1 (b) ). These results indicate that the mutation in the CPT-K5 topoisomerase I gene is moderate, most probably point mutation(s) in the structural gene. This is supported by the fact that the peptide maps of the wild-type and the mutant enzyme are indistinguishable (10 (24) (Fig.3) . These nucleotide substitutions may not be due to artifacts during cloning and/or subcloning procedures because two independent cDNA clones (K3 and K1O) isolated from independent libraries gave the same result. The nucleotide sequence encoding the wild-type topoisomerase I was identical to the corresponding region of a 3.6 kb topoisomerase I cDNA isolated from a human placental library (24) , except for two base differences: one, A at Asp-583(GAC) in our wild-type sequence is replaced by G to change to Gly-583(GGC) in the placental sequence, and the other, a neutral mutation, A at Thr-591(ACA) in our wild-type sequence Fig. 2 ).
replaced by G to change Thr-591(AC!) in the latter sequence.
The sequences of these sites of the cDNA used as a probe for the screening was the same as those of our wildtype one. Amino acid sequences of yeast, human and vaccinia vrus type I topoisomerases surrounding the mutation sites are snmarized in Fig. 4 (17, (24) (25) (26) . This comparison shows that the region in which two mutations occurred is highly conserved.
Expression of cloned topoisomerase I cDNA in E. coli as a fusion protein To know whether the two mutations found in the CPT-K5 cDNA are responsible for the resistance, we tried to express the mutated cDNA in E. coli. To express the wild-type topoisomerase I, a 3.0 kb cDNA (encoding the protein from the residue-163 over to 3'noncoding region) was excised with EcoRI from clone W3 and then inserted into pRIT2T expression vector in which the protein encoded by the cDNA was fused to the 30 kDa N-tenrinal portion of S. aureus Protein A (pRrTWT). To express the mutated protein, a 2.0 kb HindI-HindH fragment of pRITWT was replaced by that of clone K3 which contains the two mutation sites as shown in Fig. 5, (pRITK5) . After induction, the crude extracts were made as described in 'Materials and Methods'. Topoisomerase I activities of these lysates were measured (Fig.  6 ). The lysates from both E. coli cells showed similar DNA relaxation activity in the presence or absence of Mg2+ which is essential for the activity of the bacterial topoisomerase 1 (17) (Fig.   6 ,janes 4 to 6). The Figure 7 . Effect of CPT on the partially purified fusion topoisomerase I. Fusion enzymes in the crude lysates were partially purified with heparin-Sepharose as described in 'Materials and Methods.' and the relaxation activities were assayed in the absence (lanes 2 and 7) or presence of CPT at 1.0 (lanes 3 and 8) , 5 .0 (lanes 4 and 9), 50 (lanes 5 and 10), and 125 uM (lanes 6 and 11). Lanes 2-6, the wild-type fusion topoisomerase I; lanes 7-11, the CPT-K5 fusion topoisomerase I. Lane 1, substrate ColEl DNA only. harboring only the vector showed no such band (Fig. 6(b) ). The lysates also contained several additional immunoreactive polypeptides (probably proteolytic products of the 100 kDa polypeptide). It is to be ascertained whether the 88 kDa immunoreactive protein possesses an enzymatic activity. The major band with low molecular weight (30 kDa) lysate of the vector-transformed E. coli cells seemed to be a Protein A' which binds to IgG (27) . These results indicate that the fusion protein of topoisomerase I linked to Protein A' was expressed in E. coli, and exhibited the eukaryotic topoisomerase I activity.
CPI resistance of topoisomerase I activities of the fusion proteins To assess the resistance to CPT of the fusion protein, the topoisomerase I activity was partially purified from the lysates by chromatography on heparin-Sepharose as described in t t 'Materials and Methods.' Each activity was eluted at 0.6-0.7 M KCl, separated from the bacterial topoisomerase I eluting at a higher salt concentration. Immunoblot analysis showed that two major polypeptides (100 kDa and 88 kDa) im bot arilly purified active fractions reacted with the i-_io IG as detected in the crude lysates (data not shown). Pig 7 shows the effect of CPr on the partially purified fusion topoisomerase I activities. When added to the active fraction (2 unisass) of the wild-type fusion protein, CPT inhibited the ra n activty at 1 /AM or higher (Fig. 7, lanes 3-6) whereas the wtivity of the CPIT-K5 was not inhibited at all up 125 FM (Fig. 7, lanes 7-11) . From these results, the index of the fusion CPT-K5 topoisomerase I is calculated to be > 125. This value is consistent with that of the native CPT-K5 topoisomerase I (10).
Prediction of conformational change of human t I at the mutation sites
The conformation of a protein has been amply discussed in relation to the hydrophobicity-hydrophilicity of amino acids, to helix-turn structure, etc. (28, 29) . We have employed the method of Nishikawa and Ooi (20) to predict a conformation of human DNA topoisomerase I and the effect of the mutations on it. N14 value was calculated for each amino acid residue along the entire length of the protein. In Fig. 7 , the values around the mutation sites were plotted. The result predicted that the region containing the mutations was protruding toward the surface of the molecule, and the mutation replacing aspartic acid to glycine makes the region recess from the surface.
DISCUSSION
We have isolated cDNAs of DNA topoisomerase I from a CPTresistant human lymphoblastic cell line (CPT-K5) possessing a CPT-resistant topoisomerase I, and from its parental cells (RPMI8402). We identified two mutations in the CPT-K5 cDNA by sequence analyses. When the mutant topoisomerase I was expressed in E. coli as a fusion protein linked to Protein A', the fused protein exhibited the same degree of resistance to CPT as the native CPT-K5 resistant enzyme. These results indicate that the mutations found in the conserved region located near the Cterminus are responsible for the resistance of the CPT-K5 enzyme to CPT; the finding that the mutated topoisomerase I expressed in E. coli maintained the same degree of resistance to the drug excluded the possibility of the change(s) of post-translational modification of the enzyme being the cause of the resistance.
We found mutations at two sites in the CPT-K5 cDNA. However, it is not clear which mutation is responsible for the resistance. The amino acid residues corresponding to the position 533 of human topoisomerase I are aspartic acid for all species compared (Fig. 4) , with the exception of glycine in the CPT-K5 topoisomerase I, whereas the residues corresponding to the position 583 are variable, i,e. glycine for all the enzymes compared except for the wild-type and brain stem topoisomerase I. Taking into account the fact that yeast enzymes are of glycinetype and is sensitive to CPT, one could argue that the differences at residue 583 (Asp or Gly) among the human enzymes are the result of a polymorphism of the genome unrelated to the CPTresistance, and the mutation at this position as well as that at 533 may have occurred in the course of establishing the CPT-K5 cell line. If this is correct, the key mutation responsible for the resistance might be the one at 533 (Asp-Gly). In order to clarify this point, in vitro mutagenesis to create single mutation at either site is under investigation.
Although we have not yet compared the N-terminal region corresponding to 23 amino acids between the wild-type and the CPT-K5 topoisomerase I cDNAs, the finding that the resistance was expressed as a fusion protein lacking N-terminal 162 amino acid residues suggests that this region is not involved in the acquisition of CPT-resistance. It was shown earlier that the Nterminal region is not involved in the relaxation activity by the findings that a 68 kDa proteolytic product exhibits the relaxation activity in vitro (30) and CPT-resistance as well (31) . It is tempting to speculate that the N-terminal region plays a role in the interaction with regulatory molecules and/or specific sequences(s) of DNA.
One model for inhibition by CPT is that CPT binds avidly to some specific site(s) on the covalent topoisomerase I-DNA complex, thereby stabilizing the complex and blocking the resealing step of the reaction cycle (3) . Perhaps the mutations in the CPT-K5 enzyme confer resistance by altering this drugbinding site(s) of the complex. This hypothesis is supported by the prediction on the secondary structure of the enzyme that the mutation sites seem to be facing toward the outer surface of the protein (Fig. 8) . Furthermore, the finding that the region, where mutations were detected, is within the most conserved region along the sequence of the enzyme strongly suggests that this region plays an important role in the catalysis, especially in the latter half of the nicking and closing reactions, the second functional site detected in addition to the tyrosine residue-723 forming the phosphodiester bond with nicked 3'-end of DNA (13) . The fact that the mutant enzyme forms a more stable cleavable complex in the absence of CPT (11) favors the hypothesis.
Although there have been several reports on drug-resistant topoisomerases (3) , little is known about the mechanism of the resistance with a few exceptions. An amber mu-ioninthe gene 39, which encodes one of subunits of T4 phage topoisomerase (type II enzyme) is proposed to be responsible for m-AMSAresistance in the phage growth (32) . In this cas, an altered property of the drug-resistant enzyme is very similar to that of the CPT-K5 enzyme, i.e. the mutant enzyme forms a more stable cleavable complex in the absence of the drug. This suggests that the stability of the DNA-protein cleavable complex in the absence of the drug is closely related to the drug resistance of these enzymes. Recently, Shuman et al. showed that vaccinia virus topoisomerase I is resistant to CPT (33), although amino acids corresponding to the mutation sites in the CPT-K5 enzyme are of the sensitive type (Fig. 4) . According to the prediction of the terdtay stucture of vaccinia virus topoisomerase I by the method of Nishikawa and Ooi (20) , the protein assumes quite different conformation around these sites from others (data not shown). This difference might account for the resistance to CPT of the vaccmia virus topoisomerase I.
Recentdy one of the CPT derivatives, CPT-l1, has proved to be remarkably effective as an antitumor agent with reduced side effects (34) . In view of the clinical usefulness of CPT derivatives, the identification of the mutation sites of CPT resistant topoisomerase I is potentially useful for modeling novel derivatives acting against CPT resistant tumor cells. Further studies of the resistance mechanism to CPT will not only provide useful information for clinical intervention in cancer chemotherapy but also a better understanding of the mechanism of action of this important enzyme.
